TY - JOUR
T1 - Progress report on new antiepileptic drugs
T2 - A summary of the Third Eilat Conference
AU - Bialer, M.
AU - Johannessen, S. I.
AU - Kupferberg, H. J.
AU - Levy, R. H.
AU - Loiseau, P.
AU - Perucca, E.
PY - 1996/11
Y1 - 1996/11
N2 - The Third Eilat Conference on New Antiepileptic Drugs was held at the Royal Beach Hotel from May 27 to May 30, 1996. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss critical issues in drug development, new antiepileptic drugs (AEDs) in development, progress reports and recent findings of newly marketed AEDs, the use of AEDs in special populations and their utilization in non-epileptic disorders. Over the last seven years, six new AEDs have been introduced worldwide and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, topiramate and vigabatrin. Drugs in development include those at an advanced stage, such as remacemide and tiagabine, as well as those just entering clinical trials, such as rufinamide (CGP 331010) and levetiracetam (ucb LO59). The following is a summary of the presentations for drugs in development and recent findings on newly marketed drugs.
AB - The Third Eilat Conference on New Antiepileptic Drugs was held at the Royal Beach Hotel from May 27 to May 30, 1996. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss critical issues in drug development, new antiepileptic drugs (AEDs) in development, progress reports and recent findings of newly marketed AEDs, the use of AEDs in special populations and their utilization in non-epileptic disorders. Over the last seven years, six new AEDs have been introduced worldwide and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, topiramate and vigabatrin. Drugs in development include those at an advanced stage, such as remacemide and tiagabine, as well as those just entering clinical trials, such as rufinamide (CGP 331010) and levetiracetam (ucb LO59). The following is a summary of the presentations for drugs in development and recent findings on newly marketed drugs.
KW - antiepileptic drug development
KW - clinical trial design
KW - drug approval
UR - http://www.scopus.com/inward/record.url?scp=0030297333&partnerID=8YFLogxK
U2 - 10.1016/S0920-1211(96)00081-2
DO - 10.1016/S0920-1211(96)00081-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8956930
AN - SCOPUS:0030297333
SN - 0920-1211
VL - 25
SP - 299
EP - 319
JO - Epilepsy Research
JF - Epilepsy Research
IS - 3
ER -